Advances in PH Journal
Advances in Pulmonary Hypertension Winter 2003 (Vol 2, No 4)
- Editor’s Memo: Predicting Future Directions in Pulmonary Hypertension
The future of the diagnosis and treatment of pulmonary arterial hypertension (PAH) is uncertain, but it is much more promising than it was a decade ago. Intravenous prostacyclin has changed the course of this disease, and now one oral agent is approved for use and clearly has an impact on PAH.
- Profiles in Pulmonary Hypertension: Editor’s Memo Predicting Future Directions in Pulmonary Hypertension
He vividly remembers the first patient—a woman about 30 years old with primary pulmonary hypertension (PH) and unstable angina, “very blue,” and hardly any measurable cardiac output. She was among the patients seen in the early 1980s at a Cambridge, United Kingdom, hospital who were dying, the focus of frenetic activity by Tim Higenbottam, MD, FRCP, and his colleagues in a lung transplantation program.
- Severe Angioproliferative Pulmonary Hypertension: The Lung Circulation Between Vasoconstriction and Cancer
The rather recent development of specific antibodies and molecular probes allows the identification, localization, and colocalization of growth factor genes and proteins, transcription factors, enzymes, oncogenes, and markers of cell growth and cell death.
- What’s on the Horizon in Therapy, From Current Approaches to Experimental Agents
The past several years have seen dramatic changes in the therapeutic options and outlook for patients with pulmonary arterial hypertension (PAH).
- New Directions in Pulmonary Hypertension: Expanding the Spectrum of End Points to Enhance Clinical Evaluation
As new therapies emerge and reshape the future of management in pulmonary arterial hypertension (PAH), the end points used to diagnose PAH and evaluate the safety and efficacy of these new treatments are also evolving.
- A Roundtable Discussion
Future Directions: An Expert Panel Explores the Challenge of Halting Progression and Reversing the Pathology of PAH
